MYD88 and breast carcinoma: Zandi et al. assessed the baseline expression levels of MyD88 in different breast cancer cell lines—MCF7, SKBR3, MDA-MB-231, and BT-474—and observed the highest MyD88 mRNA level in MCF-7 cells.